CG 0070

Drug Profile

CG 0070

Alternative Names: CG0070

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer Cold Genesys
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bladder cancer

Most Recent Events

  • 21 Sep 2017 CG 0070 is still in phase II/III trials for Bladder cancer in USA
  • 15 May 2017 Interim efficacy data from a phase II trial in Bladder cancer presented at the 112th Annual Meeting of the American Urological Association (AUA-2017)
  • 03 Apr 2017 Cold Genesys completes enrolment in its phase II trial for Bladder cancer (Second-line therapy or greater) in USA (NCT02365818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top